Russell Frank Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Russell Frank Company’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$12.1M	Buy	193,043 +65,691	+52%	+$4.37M	0.02%	831
2015 Q4	$12M	Buy	127,352 +97,758	+330%	+$9.06M	0.02%	786
2015 Q3	$2.38M	Sell	29,594 -28,088	-49%	-$3.12M	﹤0.01%	1748
2015 Q2	$6.91M	Buy	57,682 +4,846	+9%	+$579K	0.01%	1224
2015 Q1	$5.52M	Buy	52,836 +7,894	+18%	+$800K	0.01%	1194
2014 Q4	$4.36M	Sell	44,942 -6,900	-13%	-$639K	0.01%	1371
2014 Q3	$4.05M	Sell	51,842 -43,273	-45%	-$2.79M	0.01%	1411
2014 Q2	$5.11M	Sell	95,115 -39,919	-30%	-$2.37M	0.01%	1309
2014 Q1	$9.07M	Buy	135,034 +83,515	+162%	+$6.47M	0.02%	941
2013 Q4	$4.37M	Sell	51,519 -10,043	-16%	-$599K	0.01%	1300
2013 Q3	$3.94M	Buy	61,562 +7,266	+13%	+$362K	0.01%	1479
2013 Q2	$1.68M	Buy	+54,296	New	+$1.44M	﹤0.01%	1854

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Russell Frank Company's ALNY Position: Q1 2016 in Review

Russell Frank Company increased its Alnylam Pharmaceuticals (ALNY) stake by 52% in Q1 2016, buying an estimated $4.37M and bringing the position to 193,043 shares worth $12.1M. The position accounts for 0.02% of the portfolio, ranked #831.

Russell Frank Company first reported a position in ALNY in Q2 2013 and has held it in 12 quarters since. 255 funds tracked by Wall St. Rank hold ALNY as of Q1 2016.

Russell Frank Company held 193,043 shares of Alnylam Pharmaceuticals worth $12.1M as of Q1 2016.
Russell Frank Company bought 65,691 Alnylam Pharmaceuticals shares in Q1 2016, an estimated $4.37M.
Alnylam Pharmaceuticals made up 0.02% of Russell Frank Company's portfolio in Q1 2016, its #831 holding.
Russell Frank Company first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
255 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.